Literature DB >> 21038409

Frequent multiple hepatitis C virus infections among injection drug users in a prison setting.

Son T Pham1, Rowena A Bull, James M Bennett, William D Rawlinson, Gregory J Dore, Andrew R Lloyd, Peter A White.   

Abstract

UNLABELLED: Recent data indicate that multiple hepatitis C virus (HCV) infections (mixed infection, superinfection, and reinfection) are common among injection drug users (IDUs). In this study, we identified and characterized multiple HCV infection episodes among HCV-seronegative IDU prison inmates (n = 488) enrolled in the Hepatitis C Incidence and Transmission Study cohort. Incident HCV infection with detectable HCV RNA was identified in 87 subjects, 48 of whom completed additional follow-up to screen for reinfection or superinfection. All HCV RNA-detectable samples were tested for multiple infection through a series of specifically designed nested reverse-transcription polymerase chain reaction (nRT-PCR) with sequencing and HCV RNA level measurement. Sequencing revealed that 22 of 87 (25.3%) subjects were infected by two or more viruses. Nine (10.3%) subjects were designated as prevalent cases of incident mixed infection, because two distinct HCV strains were detected at the first viremic time point. Fifteen further cases of multiple HCV infection (superinfection or reinfection) were identified, two of which also showed baseline incident mixed infections. The incidence of new HCV infection (superinfection and reinfection) during follow-up was 40/100 person-years (95% confidence interval, 33-44/100 person-years). Spontaneous clearance of viruses from one subtype and persistence of the other subtype after mixed infection was observed in eight subjects. In these subjects, the virus with higher HCV RNA levels superseded the other.
CONCLUSION: This study comprehensively analyzed frequent multiple HCV infections in a high-risk cohort and provides further insight into infection dynamics and immunity after exposure to variant viral strains. The data presented suggest that HCV RNA levels play an important role in viral competition.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21038409     DOI: 10.1002/hep.23885

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  49 in total

1.  Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.

Authors:  G V Matthews; S T Pham; M Hellard; J Grebely; L Zhang; A Oon; P Marks; I van Beek; W Rawlinson; J M Kaldor; A Lloyd; G J Dore; P A White
Journal:  Clin Infect Dis       Date:  2011-01-31       Impact factor: 9.079

Review 2.  Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C.

Authors:  Eleanor M Wilson; Elana S Rosenthal; Sarah Kattakuzhy; Lydia Tang; Shyam Kottilil
Journal:  Clin Microbiol Rev       Date:  2016-10-19       Impact factor: 26.132

3.  Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Authors:  Chaturaka Rodrigo; Melanie R Walker; Preston Leung; Auda A Eltahla; Jason Grebely; Gregory J Dore; Tanya Applegate; Kimberly Page; Sunita Dwivedi; Julie Bruneau; Meghan D Morris; Andrea L Cox; William Osburn; Arthur Y Kim; Janke Schinkel; Naglaa H Shoukry; Georg M Lauer; Lisa Maher; Margaret Hellard; Maria Prins; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  Infect Genet Evol       Date:  2017-01-05       Impact factor: 3.342

4.  Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Authors:  Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash
Journal:  J Clin Virol       Date:  2020-01-27       Impact factor: 3.168

Review 5.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

6.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.

Authors:  Jason Grebely; Son Truong Pham; Gail V Matthews; Kathy Petoumenos; Rowena A Bull; Barbara Yeung; William Rawlinson; John Kaldor; Andrew Lloyd; Margaret Hellard; Gregory J Dore; Peter A White
Journal:  Hepatology       Date:  2012-02-29       Impact factor: 17.425

7.  Patterns of Drug Use and Related Factors Among Prisoners in Iran: Results from the National Survey in 2015.

Authors:  Ghobad Moradi; Sonia Darvishi; Leila Asaadi; Fatemeh Azimian Zavareh; Mohammad-Mehdi Gouya; Mehrzad Tashakorian; Ramin Alasvand; Amjad Mohamadi Bolbanabad
Journal:  J Prim Prev       Date:  2020-02

8.  Model-based estimation of superinfection prevalence from limited datasets.

Authors:  Daniel B Reeves; Amalia S Magaret; Alex L Greninger; Christine Johnston; Joshua T Schiffer
Journal:  J R Soc Interface       Date:  2018-02       Impact factor: 4.118

9.  Dynamics of HCV RNA levels during acute hepatitis C virus infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Tanya Applegate; Gail V Matthews; Janaki Amin; Kathy Petoumenos; Margaret Hellard; William Rawlinson; Andrew Lloyd; John Kaldor; Gregory J Dore
Journal:  J Med Virol       Date:  2014-07-08       Impact factor: 2.327

10.  The role of virulence in in vivo superinfection fitness of the vertebrate RNA virus infectious hematopoietic necrosis virus.

Authors:  Alison M Kell; Andrew R Wargo; Gael Kurath
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.